Search PubMed⌕ Search

Biomedical subjects

T G Peters

Publications and source records attributed to T G Peters.

64 records · Page 4Linked to original sources
PubMed1979

Acute rejection episodes and long-term transplant function.

From 1974 to 1976, 114 kidneys transplanted to 108 patients underwent acute rejection episodes. With repeated rejections there was an increased likelihood of recovery without subsequent rejections, eg, 59% of kidneys that had three rejections regained prolonged good function. Repetitive rejections did not increase mortality. Discriminate analysis of the best serum creatinine level or creatinine clearance within 30 days of rejection and the time interval between rejection episodes correctly predicted the outcome of second rejections in 20/25 cases and correctly predicted the outcome of third rejections in 23/29 cases. Treatment of a third rejection was successful in 70% of kidneys if the best serum creatinine level was less than 2 mg/dL after the second rejection and was successful in 77% of kidneys if the time interval between second and third rejections was longer than one month.

Acute Disease↗
PubMed1977

Danazol therapy in hormone-sensitive mammary carcinoma.

The effect of Danazol, a synthetic gonadotropin inhibitor, on two groups of Sprague-Dawley rats with dimethylbenze (a) anthracine (DMBA) induced mammary carcinoma was studied. Twenty-four (83%) of 29 control animals developed mammary tumors. Forty-four rats in one treatment group received Danazol after tumor reached 0.5 cm in diameter. Twenty-nine (66%) demonstrated tumor regression (p less than 0.005) and in 16 (36%) tumor disappeared (p less than 0.005). In a second treatment group (given Danazol daily after administration of DMBA), only seven of 50 rats (14%) developed palpable mammary carcinoma (p less than 0.0005). Danazol therapy resulted in regression of established mammary carcinoma in rats, and produced a striking inhibition of carcinogenesis in those animals treated from the time DMBA was administered. Danazol is clinically safe; studies using it in the treatment of breast cancer in women who are candidates for hormonal ablative therapy seem warranted.

9,10-Dimethyl-1,2-benzanthracene↗
PubMed1977

Antithrombin III deficiency causing postsplenectomy mesenteric venous thrombosis coincident with thrombocytopenia.

The most commonly recognized cause of mesenteric venous thrombosis following splenectomy is hypercoagulation secondary to reactive thrombocytosis. A case is reviewed in which hypercoagulation followed splenectomy for idiopathic thrombocytopenic purpura (ITP) in spite of persistent thrombocytopenia. Episodic mesenteric venous occlusion occurred due to antithrombin III deficiency. This hypercoagulable state may be the cause of primary acute mesenteric venous occlusive disease. Symptoms and signs suggesting thrombosis in the portal circulation demand immediate coagulation studies since even in the thrombocytopenic patient thrombotic proglems can occur. Surgical intervention is the treatment of choice for segmental small bowel ischemia; warfarin therapy is indicated when there is evidence of antithrombin III deficiency.

Adult↗
PubMed1977

Minimal breast cancer: a clinical appraisal.

Eighty-five patients with a diagnosis of minimal breast cancer were evaluated. The predominant lesion was intraductal carcinoma, and axillary metastases occurred in association with minimal breast cancer in seven of 96 cases. One death occurred due to minimal breast cancer. Bilateral mammary carcinoma was evident in 24% and bilateral minimal breast cancer in 13% of the patients. The component lesions of minimal breast cancer have varied biologic activity, but prognosis is good with a variety of operations. The multifocal nature of minimal breast cancer and the potential for metastases should be recognized. Therapy should include removal of the entire mammary parenchyma and low axillary nodes. The high incidence of bilateral malignancy supports elective contralateral biopsy at the time of therapy for minimal breast cancer.

Adult↗
PubMed1977

Dose dependence of immunopotentiation and tumor regression induced by levamisole.

Breast cancer was induced in female Sprague-Dawley rats by 7,12-dimethylbenz(a)anthracene. Once tumors had become established, they were treated with varying doses of the immunopotentiating drug, levamisole. Tumor growth was measured in the various dosage groups, and at 6 months after tumor induction the animals were sacrificed. Their immunological competence at this time was measured by the mitogen responses of splenic lymphocytes. Untreated animals with breast cancer were found to be immunosuppressed compared to normal animals. The drug levamisole resulted in immunopotentiation, but at high doses it was immunosuppressive. Tumor regression was observed at doses that resulted in immunopotentiation, but not at high doses. There was a significant correlation between immune competence and tumor regression. It is concluded that levamisole can cause regression of breast cancer in the rat but that this effect is critically dependent on the dose of the drug; these observations confirm previous studies carried out on human cells in vitro. It is recommended that high doses of the drug be avoided in human clinical trials and that the patients who receive this drug should have their immune responses carefully monitored.

9,10-Dimethyl-1,2-benzanthracene↗
PubMedDate not supplied

Feeding stoma surgery on a nutritional support service.

Thirty patients undergoing feeding stoma operation over a 2 1/2 yr period were managed by the nutritional support service. The policy of preoperative nutritional support of these generally ill and malnourished patients contributed to operative survival and discharge from the hospital for 23 patients; only one death 21 days postoperatively was directly attributable to the feeding stoma procedure. Nonfatal complications of the surgery occurred in nine cases, and required reoperation in three instances. Early stoma use was the rule, and there were 10 documented cases of long-term stoma use averaging 14 months. Three-month survival of 19 patients (63%), and six-month survival of 13 patients (43%) along with early discharge from the hospital for most patients attest to efficacy and ease of stoma use. An essential feature contributing to diminished postoperative problems was prestoma surgery nutritional support. Continuity of feeding stoma planning and patient care may be best achieved when a nutritional support service is involved through the entire course of management.

Adult↗